治疗新冠肺炎口服小分子药物研究进展

摘要/Abstract

摘要： 新型冠状病毒（SARS-CoV-2）引发的急性呼吸道传染性疾病在全球大规模流行，严重威胁人类生命安全，迫切需要有效的抗新冠肺炎（COVID-19）药物。疫苗、抗体和小分子药物成为战胜疫情的关键。口服小分子药物具有成本低、易生产、方便运输等优点，已成为开发抗COVID-19特效药的焦点。近日，有两款口服小分子药物成功获批上市，用于治疗早期轻症COVID-19患者，这为全球COVID-19患者的治疗和预防打了一剂强效“加强针”。鉴于此，本研究基于当前口服小分子药物研究和发展现状，简要梳理了治疗COVID-19口服小分子药物的开发策略，挑选目前已上市或正处于临床试验的治疗COVID-19口服小分子药物，总结其临床治疗效果、作用特点及作用机制，以期为口服小分子抗COVID-19药物的开发提供一定参考。

关键词: font-size:medium, ">新冠病毒；新冠肺炎；口服小分子药物；药物开发

Abstract: Corona virus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are spreading globally on a large scale， seriously threatening the safety of human life， and the world urgently needs effective against COVID-19 drugs. Vaccines， antibodies and small molecule drugs have become the key to defeating the epidemic of COVID-19. Due to the low cost， easy production， and convenient transportation of oral small molecule drugs， they have become the focus of the development of sovereign remedy to ultimately defeat the COVID-19. Recently， two oral small molecule drugs have been successfully approved for market to treat patients with early mild COVID-19. This is a powerful "strengthening shot" for the treatment and prevention of COVID-19. This paper briefly summarizes the current anti-coronavirus oral small molecule drug development strategies， and selects the most representative and promising oral small molecule drugs， reviews their clinical therapeutic effects， characteristics of action， and mode of action， to provide some references for the development of novel oral small molecule anti-coronavirus drugs.

Key words: font-size:medium, ">SARS-CoV-2； COVID-19； Oral small molecule drugs；Drug development

中图分类号:

卞金磊, 张立翱, 徐熙, 李志裕. 治疗新冠肺炎口服小分子药物研究进展[J]. 中国医药导刊, 2022, 24(1): 16-26.

BIAN Jinlei, ZHANG Li′ao, XU Xi, LI Zhiyu. Oral Small Molecule Drug Discovery for the Treatment of COVID-19[J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2022, 24(1): 16-26.

参考文献

[1]Zhou P， Yang XL， Wang XG， et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin [J]. Nature， 2020， 579(7798)： 270-273.
     [2]国家卫生健康委员会.关于修订新型冠状病毒肺炎英文命名事宜的通知(国卫医函〔2020〕70号) [EB/OL].(2020-02-22)[2021-12-27]. http：// www.nhc.gov.cn/yzygj/s7653p/202002/33393aa53d984ccdb1053a52b6bef 810.shtml.
     [3]新华网. 世界卫生组织将新型冠状病毒感染的肺炎命名为“Covid-19” [EB/OL]. (2020-02-11)[2022-01-06]. http：//www.xinhuanet.com/politics/2020-02/11/c_1125561343.htm.
     [4]University JH. COVID-19 dashboard by the center for systems science and engineering (CSSE) at Johns Hopkins University (JHU) [EB/OL]. (2022-01-06)[2022-01-06]. https：//coronavirus.jhu.edu/map.html.
     [5]Xiu S， Dick A， Ju H， et al. Inhibitors of SARS-CoV-2 entry： current and future opportunities [J]. J Med Chem， 2020， 63(21)： 12256-12274.
     [6]Perlman S， Netland J. Coronaviruses post-SARS： update on replication and pathogenesis [J]. Nature Reviews Microbiology， 2009， 7(6)： 439-450.
     [7]Ziegler CGK， Allon SJ， Nyquist SK， et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues [J]. Cell， 2020， 181(5)： 1016-1035.e1019.
     [8]Malone B， Urakova N， Snijder EJ， et al. Structures and functions of coronavirus replication-transcription complexes and their relevance for SARS-CoV-2 drug design [J]. Nature Reviews Molecular Cell Biology， 2022， 23(1)： 21-39.
     [9]Chan JFW， Kok KH， Zhu Z， et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan [J]. Emerging Microbes & Infections， 2020， 9(1)： 221-236.
     [10]Sheahan TP， Sims AC， Zhou S， et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice [J]. Sci Transl Med， 2020， 12(541)： DOI： 10.1126/scitranslmed.abb5883.
     [11]Kabinger F， Stiller C， Schmitzová J， et al. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis [J]. Nat Struct Mol Biol， 2021， 28(9)： 740-746.
     [12]Wang M， Cao R， Zhang L， et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro [J]. Cell Res， 2020， 30(3)： 269-271.
     [13]Jayk Bernal A， Gomes Da Silva MM， Musungaie DB， et al. Molnupiravir for oral treatment of COVID-19 in nonhospitalizedpatients [J]. N Engl J Med， 2021， 2116044.
     [14]Merck.Merck and Ridgeback’s Molnupiravir Receives U.S. FDA emergency use authorization for the treatment of high-risk adults with mild to moderate COVID-19 [EB/OL]. (2021-11-23)[2022-01-06]. https：//www.merck.com/news/merck-and-ridgebacks-molnupiravir-receives-u-s-fda-emergency-use-authorization-for-the-treatment-of-high-risk-adults-with-mild-to-moderate-covid-19/.
     [15]Willyard C. How antiviral pill molnupiravir shot ahead in the COVID drug hunt [EB/OL]. (2021-10-10)[2022-01-06]. https：//www.nature.com/articles/d41586-021-02783-1.
     [16]Berliba E， Bogus M， Vanhoutte F， et al. Safety， pharmacokinetics， and antiviral activity of AT-527， a novel purine nucleotide prodrug， in hepatitis C virus-infected subjects with or without cirrhosis [J]. Antimicrob Agents Chemother， 2019， 63(12)： e01201-01219.
     [17]Atea.Atea Pharmaceuticals provides update and topline results for phase 2 MOONSONG trial evaluating AT-527 in the outpatient setting [EB/OL]. (2021-10-19)[2022-01-06]. https：//ir.ateapharma.com/news-releases/news-release-details/atea-pharmaceuticals-provides-update-and-topline-results-phase-2.
     [18]Anand K， Ziebuhr J， Wadhwani P， et al. Coronavirus main proteinase (3CLpro) structure： basis for design of anti-SARS drugs [J]. Science， 2003， 300(5626)： 1763-1767.
     [19]Fan K， Ma L， Han X， et al. The substrate specificity of SARS coronavirus 3C-like proteinase [J]. Biochemical and Biophysical Research Communications， 2005， 329(3)： 934-940.
     [20]Ramajayam R， Tan KP， Liang PH. Recent development of 3C and 3CL protease inhibitors for anti-coronavirus and anti-picornavirus drug discovery [J].BiochemSoc Trans， 2011， 39(5)： 1371-1375.
     [21]Dragovich PS， Prins TJ， Zhou R， et al. Structure-based design， synthesis， and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. incorporation of P1 lactam moieties as l-glutamine replacements [J]. J Med Chem， 1999， 42(7)： 1213-1224.
     [22]Owen Dafydd R， Allerton Charlotte MN， Anderson Annaliesa S， et al.An oral SARS-CoV-2 MPRO inhibitor clinical candidate for the treatment of COVID-19 [J].Science， 2021，374(575)：1586-1593.
     [23]Pfizer.Pfizer′s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study [EB/OL]. (2021-11-05) [2022-01-06]. https：//www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate.
     [24]Pfizer. Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death [EB/OL]. (2021-12-14)[2022-01-06]. https：//www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-additional-phase-23-study-results.
     [25]辛雨. 美国批准新冠口服药紧急使用权[N]. 中国科学报，2021-12-24(001).
     [26]Hoffman RL， Kania RS， Brothers MA， et al. Discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19 [J]. J Med Chem， 2020， 63(21)： 12725-12747.
     [27]Zhao Y， Fang C， Zhang Q， et al. Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332 [J]. Protein Cell， 2021， 22：1-5.
     [28]Shionogi. Shionogi presents COVID-19 therapeutic agent results at the ISIRV-WHO virtual conference [EB/OL]. (2021-10-21) [2022-01-06]. https：//www.shionogi.com/global/en/news/2021/10/e-211021_2.html.
     [29]口服3CL蛋白酶抑制剂：盐野义公布临床结果，预计2022年1季度在日本上市 [EB/OL]. (2021-11-21)[2021-11-24]. https：//mp.weixin.qq.com/s/KzCnAdqD171luob8WJT_2A.
     [30]Dai W， Zhang B， Jiang XM， et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease [J]. Science， 2020， 368(6497)： 1331-1335.
     [31]许叶春，柳红，李剑峰，等. 抗新冠肺炎药物研究进展 [J]. 中国生物工程杂志， 2021， 41(6)： 111-118.
     [32]Flavio ACF， John M， Carlos GW， et al. Proxalutamide significantly accelerates viral clearance and reduces time to clinical remission in patients with mild to moderate COVID-19： results from a randomized， double-blinded， placebo-controlled trial [J]. Cureus， 2021， 13(2)： 3(2)：e13492.
     [33]樊巍，冷舒眉. 国产新冠口服特效药进展如何 [N]. 环球时报，2021-12-02(011).
     [34]开拓药业. 开拓药业公布普克鲁胺治疗轻中症新冠患者Ⅲ期临床试验中期分析进展[EB/OL]. (2021-12-27)[2021-12-30]. https：//www.kintor.com.cn/news/246.html.
     [35]国家药品监督管理局.国家药监局应急批准腾盛华创医药技术（北京）有限公司新冠病毒中和抗体联合治疗药物安巴韦单抗注射液（BRII-196）及罗米司韦单抗注射液（BRII-198）注册申请[EB/OL]（2021-12-08）[2022-01-06]. https：//www.nmpa.gov.cn/yaowen/ypjgyw/20211208212528103.html.
     [36]Brii Bio， Brii Bio Initiates Submission of Emergency Use Authorization Filing to U.S. FDA for BRII-196/BRII-198， its monoclonal sntibody Combination therapy for non-hospitalized COVID-19 patients at high tisk of clinical progression to severe disease [EB/OL]. (2021-10-09) [2022-01-06]. http：//www.briibio.com/news-detial.php?id=370#news.
     [37]WHO.WHO Coronavirus (COVID-19) Dashboard [EB/OL]. (2022-01-06) [2022-01-06]. https：//covid19.who.int/.

快速检索引用检索图表检索高级检索